(Q37888672)

24 August 2017

1 reference

title

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

1

Sohita Dhillon

1 reference

24 August 2017

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

71

1 reference

24 August 2017

8

1 reference

24 August 2017

1071-1091

1 reference

https://scigraph.springernature.com/pub.10.2165/11202240-000000000-00000

24 August 2017

0 references

cites work

HIV lipodystrophy and its metabolic consequences: implications for clinical practice

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Pathogenesis and treatment of HIV lipohypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Waist to hip ratio and trunk to extremity fat (DXA) are better surrogates for IMCL and for visceral fat respectively than for subcutaneous fat in adolescent girls

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Severity of lipodystrophy is associated with decreased health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Abdominal subcutaneous adipose tissue: a protective fat depot?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Increased cardiovascular disease risk indices in HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Cardiovascular complications of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety e

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202240-000000000-00000

Lipodystrophy and quality of life of HIV-infected persons.

21 January 2018

1 reference

12 December 2020

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction

1 reference

12 December 2020

Endothelial function is impaired in HIV-infected patients with lipodystrophy

1 reference

12 December 2020

Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.

1 reference

12 December 2020

Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy

1 reference

12 December 2020

Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

1 reference

12 December 2020

Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes As

1 reference

12 December 2020

Improved survival in HIV-infected persons: consequences and perspectives

1 reference

12 December 2020

Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.

1 reference

12 December 2020

Progression of retinopathy in insulin-treated type 2 diabetic patients

1 reference

12 December 2020

10.2165/11202240-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21668043

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21668043